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LETTERS TO THE EDITOR
Limitation of vWf
Meta-Analysis in LMWH Comparison
Differences in clinical efficacy between unfractionated heparin
(UFH) and low molecular weight heparin (LMWH) but also
between several LMWH preparations are a hot topic in research
due to differences in study results: enoxaparin proved superiority
over UFH (1,2), whereas dalteparin and nadroparin showed only
equivalence (3,4). As there is a lack of trials directly comparing
LMWHs, some investigators tried to answer the question for the
most effective LMWH preparation with data from comparative
meta-analysis: Montalescot et al. (5) published a post hoc analysis
in JACC in which they postulated differences between dalteparin
and enoxaparin concerning their action on circulating von Wille-
brand factor (vWf) levels in patients with unstable angina. This
could be of clinical importance as vWf has been shown previously
to be a predictor of outcome in acute coronary syndrome (6).
However, in scrutinizing the analytical method in Montalescot’s
work, serious drawbacks are revealed.
Montalescot et al. (5) presented a post hoc analysis that investi-
gated, in part, results from two prospective trials with enoxaparin
(1,2), one prospective trial with PEG-hirudin (PEGHIRUD 022)
and one registry with dalteparin (USIC registry). A point of criticism
is the comparison of prospective studies with a registry especially if
randomized prospective data are available (3).
In addition, the levels of vWf on UFH treatment in this
meta-analysis were obtained by pooling data from the mentioned
studies. These pooled UFH data were compared with the LMWH
results of the individual studies and the registry, respectively. This
is a questionable procedure and weakens the results. The proper
way would have been to compare the pooled UFH data with
pooled results from all cited LMWH studies.
Finally, p values were only calculated for the comparisons of
vWf levels between enoxaparin and, respectively, dalteparin and
UFH, but not directly between the LMWHs themselves, which is,
of course, impossible regarding the chosen analytical method. Only
direct comparisons (also of other surrogate markers) could provide
this data.
In our opinion, it is not correct from a scientific point of view to
draw any conclusions concerning the relative efficacy of dalteparin
and enoxaparin from these results. Although a proper post hoc
analysis can be a helpful tool in certain cases, the question for the
most effective LMWH should preferably be answered by head-to-
head studies. If these studies are not available (e.g., because of cost
reasons), the investigation of surrogate markers of hemostasis
could be feasible to predict clinical outcome and to compare
different LMWH preparations.
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REPLY
Interestingly, Dr. Ho¨dl has focused his attention only on the two
low molecular weight heparin (LMWH) treatments, whereas four
anticoagulant treatments were examined in our study. Clearly, Dr.
Ho¨dl drew more definite conclusions than we did between the two
LMWHs, because we were cautious enough not to compare
dalteparin to enoxaparin (see Fig. 1 in Ref. 1), and we only
compared each new anticoagulant treatment (enoxaparin, daltepa-
rin, PEG-hirudin) to the standard of care—unfractionated hepa-
rin (UH) (1). Also, UH was the control arm in all the randomized
studies in which our patients were included. Moreover, Dr. Ho¨dl
did not consider our warning (pg. 113 of Ref. 1) stating that “the
main limitation of our study is the lack of randomization among
the four treatment groups.”
Dr. Ho¨dl discussed post hoc analyses but forgot to mention and
to refer to the first demonstration of von Willebrand factor (vWf)
as a prognosis factor of outcome in unstable angina with a
significantly better effect of enoxaparin compared to UH in
controlling the release of vWf. These data were obtained in a
prespecified substudy of the ESSENCE trial performed in several
French centers; in a double-blind fashion, patients were random-
ized to receive either enoxaparin or UH. All clinical events were
adjudicated by the end point committee of the ESSENCE trial;
the substudy was designed and conducted prospectively, and all
samples from all centers were analyzed in a blinded fashion in a
central laboratory (2). Dr. Ho¨dl suggests using data from the
randomized FRIC trial opposing dalteparin to UH, which was
published in 1997 (3); we would be very happy to collaborate with
him on this great idea and test the vWf hypothesis in the FRIC
population. Paradoxically, Dr. Ho¨dl also states that the “proper”
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